Vitamin D3 in Sensory Recovery After Digital NERVe Suture (D3NERV). (D3NERV)

August 30, 2021 updated by: University Hospital, Caen

Vitamin D3 in Sensory Recovery After Digital NERVe Suture: a Randomized Controlled Trial.

Digital nerve injuries are frequent in a FESUM center (Federation Européenne des Services d'Urgences Mains), and they need to be repaired in order to reduce the risk of hypoesthesia and to prevent painful neuroma. Several animal studies have shown that Cholecalciferol improves axonal nerve regeneration and myelination. No study has ever been done on human subjects to evaluate the nerve regeneration after Cholecalciferol supplementation.

Our hypothesis is that Cholecalciferol supplementation could improve axonal nerve regeneration and myelination after traumatic digital nerve injuries treated by microsurgical sutures and reduce the risk of hypoesthesia and neuroma.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Anticipated)

72

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Caen, France, 14000
        • Recruiting
        • Caen University Hospital
        • Contact:
          • Parienti Jean-Jacques, PHD
      • Rouen, France, 76000
        • Recruiting
        • Rouen University Hospital
        • Contact:
          • Auquit-Auckbur Isabelle, PHD
      • Saint-Herblain, France, 44800
        • Recruiting
        • Institut de la main Nantes Atlantique
        • Contact:
          • Lecoq Flore-Anne, MD
          • Phone Number: 0251844884

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 47 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Affiliated to social security scheme,
  • Wound of the palmar hand with isolated digital nerve section, requiring digital nerve microsurgical suture in the operating room by a senior surgeon,
  • Signing a free and informed consent and well-informed of the study and procedure.

Exclusion Criteria:

  • Ischemia,
  • Multiple lesion of the same nerve,
  • Pregnant or nursing women,
  • Contraindication of Cholecalciferol : known hypersensitivity, any history of hypercalcemia, hypercalciuria or renal lithiasis,
  • Cholecalciferol supplementation in the past 6 months,
  • Lesion of the same controlateral finger,
  • History of nerve lesion or hypoesthesia on the same finger,
  • History of previous neurological disorders with upper limb sensitivity disorder,
  • Impossibility to undergo the medical follow-up because of geographical, social or psychological reason,
  • Participation in another clinical trial that does not allow simultaneous participation in several clinical trials,
  • Orlistat® Treatment,
  • History of celiac disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cholecalciferol
Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
One vial every 15 days during 2 months
Placebo Comparator: Placebo
Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
One vial every 15 days during 2 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weber test (Month 6)
Time Frame: Month 6
2 point discrimination test of Weber on the side of the fingertip concerned by the wound, comparing to the controlateral arm, after 6 months.
Month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weber test (Month 12)
Time Frame: Month 12
2 point discrimination test of Weber on the side of the fingertip concerned by the wound, comparing to the controlateral arm, after 12 months.
Month 12
Resting pain on the operated finger
Time Frame: Month 2, Month 6, Month 12
VAS (Visual Analogic Scale)
Month 2, Month 6, Month 12
Neuropathic pain on the operated finger
Time Frame: Month 2, Month 6, Month 12
DN 4 (Neuropathic pain)
Month 2, Month 6, Month 12
Global functional outcome measure
Time Frame: Month 2, Month 6, Month 12
Quick DASH
Month 2, Month 6, Month 12
Cold Intolerance
Time Frame: Month 2, Month 6, Month 12
CSS (Cold Sensitivity Severity Scale)
Month 2, Month 6, Month 12
Cold Intolerance at work
Time Frame: Month 2, Month 6, Month 12
PWES (Potential Work Exposure Scale)
Month 2, Month 6, Month 12
Quality-of-life measure
Time Frame: Month 2, Month 6, Month 12
SF-36 (Study Short form 36)
Month 2, Month 6, Month 12
Return-to-work time frames
Time Frame: Month 2
Time before returning to work
Month 2
Vitamin D blood level
Time Frame: at inclusion, Month 2
at inclusion, Month 2
Adverse event and complication
Time Frame: Trough study completion
Existence of neuroma, existence of medical complication, existence of overdosage of Cholecalciferol and every other adverse event
Trough study completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 20, 2020

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

August 19, 2019

First Submitted That Met QC Criteria

October 3, 2019

First Posted (Actual)

October 4, 2019

Study Record Updates

Last Update Posted (Actual)

August 31, 2021

Last Update Submitted That Met QC Criteria

August 30, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Digital Nerve Injury

Clinical Trials on Cholecalciferol

Subscribe